SCHEMBL14010917

SCHEMBL14010917

O=C1OCC[C@@H]2C1=CO[C@@H](OCCl)[C@@H]2I

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14010720 0.74 STAT3 (0.40) STAT3
SCHEMBL14010716 0.65 — —
SCHEMBL29425858 0.60 STAT3 (0.41) STAT3
SCHEMBL31371996 0.59 STAT3 (0.56) STAT3
SCHEMBL13998201 0.59 STAT3 (0.56) STAT3
SCHEMBL10042275 0.59 STAT3 (0.50) STAT3
SCHEMBL9181141 0.51 BCL2L1 (0.35) —
SCHEMBL12654038 0.50 — —
SCHEMBL982080 0.50 — —
SCHEMBL27878847 0.48 CYP1A2 (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319042-A1 Compositions and methods for treatment of liver disease CALECO PHARMA CORP. 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319042-A1 Compositions and methods for treatment of liver disease HCCS, HAVCR2, PYGL STAT3 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback